Adjuvant Chemotherapy in Lymph Node-Negative, T1 Triple-Negative Breast Cancer.

ABSTRACT:

Background

The role of adjuvant chemotherapy in small, node-negative triple-negative breast cancer (TNBC) has not been formally assessed in clinical trials. We aimed to evaluate the benefit of adjuvant chemotherapy in this population.

Methods

This is a retrospective study using the National Cancer Database (NCDB). We included women with pathologic T1N0M0 (pT1N0M0) TNBC diagnosed between 2010 and 2019. Kaplan-Meier methods and Cox proportional models were used to compare overall survival (OS) between chemotherapy and no chemotherapy cohorts.

Results

In patients with pT1N0M0 TNBC, adjuvant chemotherapy improved OS (HR, 0.51; 95% CI, 0.47-0.55). The benefit of adjuvant chemotherapy was evidenced across all tumor sizes; T1a HR 0.51 (95% CI 0.34-0.75), T1b HR 0.55 (95% CI

SUBMITTER: Anampa JD 

PROVIDER: S-EPMC12585342 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature